Which has preferable earnings and valuation, KTTA or RNTX?

Rein Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$1.58 N/A Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A

Is KTTA or RNTX more profitable?

Rein Therapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -49.49% -46.81% Rein Therapeutics N/A N/A -63.69%

Does the media refer more to KTTA or RNTX?

In the previous week, Rein Therapeutics had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 3 mentions for Rein Therapeutics and 2 mentions for Pasithea Therapeutics. Rein Therapeutics' average media sentiment score of 0.31 beat Pasithea Therapeutics' score of 0.02 indicating that Rein Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Rein Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, KTTA or PMVP?

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$1.58 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.42 N/A

Is KTTA or PMVP more profitable?

Pasithea Therapeutics' return on equity of -49.49% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -49.49% -46.81% PMV Pharmaceuticals N/A -78.11% -70.13%

Which has higher earnings and valuation, KTTA or CTOR?

Citius Oncology is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$1.58 N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is KTTA or CTOR more profitable?

Pasithea Therapeutics' return on equity of -49.49% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -49.49% -46.81% Citius Oncology N/A -102.98% -43.49%

Do analysts rate BOLD or KTTA?

Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 444.46%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, BOLD or KTTA?

Boundless Bio is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boundless Bio N/A N/A -$58.20M -$2.86 N/A Pasithea Therapeutics N/A N/A -$20.43M -$1.58 N/A

Is BOLD or KTTA more profitable?

Pasithea Therapeutics' return on equity of -49.49% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -70.89% -47.37% Pasithea Therapeutics N/A -49.49% -46.81%

Is IMA or KTTA more profitable?

ImageneBio's return on equity of -38.99% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% Pasithea Therapeutics N/A -49.49% -46.81%

Does the media refer more to IMA or KTTA?

In the previous week, ImageneBio had 22 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 24 mentions for ImageneBio and 2 mentions for Pasithea Therapeutics. ImageneBio's average media sentiment score of 1.21 beat Pasithea Therapeutics' score of 0.02 indicating that ImageneBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Pasithea Therapeutics (KTTA) Competitors

$0.55 -0.02 (-3.33%)

As of 10:28 AM Eastern

Compare

KTTA vs. RNTX, PMVP, CTOR, BOLD, and IMA

Should you buy Pasithea Therapeutics stock or one of its competitors? Pasithea Therapeutics's main competitors and comparable companies include Rein Therapeutics (RNTX), PMV Pharmaceuticals (PMVP), Citius Oncology (CTOR), Boundless Bio (BOLD), and ImageneBio (IMA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pasithea Therapeutics compare to Rein Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

In the previous week, Rein Therapeutics had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 3 mentions for Rein Therapeutics and 2 mentions for Pasithea Therapeutics. Rein Therapeutics' average media sentiment score of 0.31 beat Pasithea Therapeutics' score of 0.02 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rein Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pasithea Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 444.46%. Rein Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 644.42%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 1.5% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Pasithea Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

Rein Therapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-49.49%	-46.81%
Rein Therapeutics	N/A	N/A	-63.69%

Rein Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

Summary

Rein Therapeutics beats Pasithea Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Pasithea Therapeutics compare to PMV Pharmaceuticals?

Pasithea Therapeutics (NASDAQ:KTTA) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A

Pasithea Therapeutics' return on equity of -49.49% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-49.49%	-46.81%
PMV Pharmaceuticals	N/A	-78.11%	-70.13%

Pasithea Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market.

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 1.5% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pasithea Therapeutics presently has a consensus price target of $3.00, indicating a potential upside of 444.46%. PMV Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 210.08%. Given Pasithea Therapeutics' higher probable upside, analysts clearly believe Pasithea Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Pasithea Therapeutics had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 2 mentions for Pasithea Therapeutics and 1 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 1.44 beat Pasithea Therapeutics' score of 0.02 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Pasithea Therapeutics	Neutral
PMV Pharmaceuticals	Positive

Summary

PMV Pharmaceuticals beats Pasithea Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Citius Oncology?

Pasithea Therapeutics (NASDAQ:KTTA) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Pasithea Therapeutics presently has a consensus price target of $3.00, indicating a potential upside of 444.46%. Citius Oncology has a consensus price target of $6.00, indicating a potential upside of 654.72%. Given Citius Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Citius Oncology is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pasithea Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.48, meaning that its stock price is 248% more volatile than the broader market.

Pasithea Therapeutics' return on equity of -49.49% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-49.49%	-46.81%
Citius Oncology	N/A	-102.98%	-43.49%

In the previous week, Pasithea Therapeutics had 1 more articles in the media than Citius Oncology. MarketBeat recorded 2 mentions for Pasithea Therapeutics and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.87 beat Pasithea Therapeutics' score of 0.02 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Pasithea Therapeutics	Neutral
Citius Oncology	Very Positive

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 1.5% of Pasithea Therapeutics shares are owned by insiders. Comparatively, 9.8% of Citius Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Citius Oncology is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Summary

Citius Oncology beats Pasithea Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Boundless Bio?

Boundless Bio (NASDAQ:BOLD) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Boundless Bio is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A

Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 444.46%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Boundless Bio and Boundless Bio both had 2 articles in the media. Boundless Bio's average media sentiment score of 0.44 beat Pasithea Therapeutics' score of 0.02 indicating that Boundless Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Boundless Bio	Neutral
Pasithea Therapeutics	Neutral

23.9% of Pasithea Therapeutics shares are owned by institutional investors. 23.1% of Boundless Bio shares are owned by company insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Pasithea Therapeutics' return on equity of -49.49% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-70.89%	-47.37%
Pasithea Therapeutics	N/A	-49.49%	-46.81%

Boundless Bio has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Summary

Pasithea Therapeutics beats Boundless Bio on 10 of the 12 factors compared between the two stocks.

How does Pasithea Therapeutics compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

ImageneBio's return on equity of -38.99% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Pasithea Therapeutics	N/A	-49.49%	-46.81%

ImageneBio currently has a consensus price target of $29.00, suggesting a potential upside of 422.99%. Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 444.46%. Given Pasithea Therapeutics' higher probable upside, analysts clearly believe Pasithea Therapeutics is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pasithea Therapeutics has lower revenue, but higher earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	78.67	-$45.35M	-$4.58	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ImageneBio has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

In the previous week, ImageneBio had 22 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 24 mentions for ImageneBio and 2 mentions for Pasithea Therapeutics. ImageneBio's average media sentiment score of 1.21 beat Pasithea Therapeutics' score of 0.02 indicating that ImageneBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ImageneBio beats Pasithea Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KTTA vs. The Competition

Export

Metric	Pasithea Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.41M	$4.00B	$7.23B	$12.87B
Dividend Yield	N/A	3.63%	2.54%	11.02%
P/E Ratio	-0.35	11.49	272.48	24.29
Price / Sales	N/A	1,304.68	608.54	79.97
Price / Cash	N/A	108.37	79.89	53.65
Price / Book	0.37	16.72	13.12	6.25
Net Income	-$20.43M	-$22.76M	$3.47B	$348.11M
7 Day Performance	17.23%	3.34%	2.05%	1.47%
1 Month Performance	22.44%	11.53%	8.25%	4.70%
1 Year Performance	-26.79%	58.10%	26.26%	17.01%

Pasithea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KTTA Pasithea Therapeutics	2.8771 of 5 stars	$0.55 -3.3%	$3.00 +444.5%	-19.0%	$18.41M	N/A	N/A	3
RNTX Rein Therapeutics	3.6324 of 5 stars	$0.79 +2.8%	$6.00 +657.6%	-30.4%	$66.43M	N/A	N/A	9
PMVP PMV Pharmaceuticals	3.604 of 5 stars	$1.28 +3.2%	$4.00 +212.5%	-9.0%	$66.29M	N/A	N/A	50	Positive News
CTOR Citius Oncology	2.4795 of 5 stars	$0.75 +7.0%	$6.00 +697.3%	-60.4%	$65.37M	N/A	N/A	N/A	Positive News Gap Down
BOLD Boundless Bio	0.8822 of 5 stars	$2.86 flat	N/A	+156.4%	$65.06M	N/A	N/A	64	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KTTA) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. RNTX, PMVP, CTOR, BOLD, and IMA

How does Pasithea Therapeutics compare to Rein Therapeutics?

Summary

How does Pasithea Therapeutics compare to PMV Pharmaceuticals?

Summary

How does Pasithea Therapeutics compare to Citius Oncology?

Summary

How does Pasithea Therapeutics compare to Boundless Bio?

Summary

How does Pasithea Therapeutics compare to ImageneBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. RNTX, PMVP, CTOR, BOLD, and IMA

How does Pasithea Therapeutics compare to Rein Therapeutics?

Does the media refer more to KTTA or RNTX?

Do analysts prefer KTTA or RNTX?

Do insiders & institutionals hold more shares of KTTA or RNTX?

Which has more risk and volatility, KTTA or RNTX?

Is KTTA or RNTX more profitable?

Which has preferable earnings and valuation, KTTA or RNTX?

Summary

How does Pasithea Therapeutics compare to PMV Pharmaceuticals?

Which has stronger earnings and valuation, KTTA or PMVP?

Is KTTA or PMVP more profitable?

Which has more volatility and risk, KTTA or PMVP?

Do institutionals and insiders have more ownership in KTTA or PMVP?

Do analysts rate KTTA or PMVP?

Does the media favor KTTA or PMVP?

Summary

How does Pasithea Therapeutics compare to Citius Oncology?

Do analysts recommend KTTA or CTOR?

Which has more volatility and risk, KTTA or CTOR?

Is KTTA or CTOR more profitable?

Does the media prefer KTTA or CTOR?

Do institutionals and insiders have more ownership in KTTA or CTOR?

Which has higher earnings and valuation, KTTA or CTOR?

Summary

How does Pasithea Therapeutics compare to Boundless Bio?

Which has stronger valuation & earnings, BOLD or KTTA?

Do analysts rate BOLD or KTTA?

Does the media favor BOLD or KTTA?

Do insiders and institutionals hold more shares of BOLD or KTTA?

Is BOLD or KTTA more profitable?

Which has more volatility & risk, BOLD or KTTA?

Summary

How does Pasithea Therapeutics compare to ImageneBio?

Is IMA or KTTA more profitable?

Do analysts rate IMA or KTTA?

Which has higher earnings & valuation, IMA or KTTA?

Do insiders & institutionals hold more shares of IMA or KTTA?

Which has more risk & volatility, IMA or KTTA?

Does the media refer more to IMA or KTTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools